The European Medicines Agency has granted marketing authorization for the anti-HIV medication INTELENCE™ (etravirine), the first next generation non-nucleoside reverse transcriptase inhibitor (NNRTI) to show efficacy in patients with NNRTI-resistant HIV. Also known as TMC125, Intelence was developed by Tibotec Pharmaceuticals, Ltd. Janssen-Cilag International NV will hold the marketing authorization. It has the potential to suppress the virus to undetectable levels. Intelence, along with a boosted protease inhibitor and other antiretroviral medicinal products, is indicated for the treatment of HIV type 1 infection in adult patients with experience of antiretroviral treatment. The recommended oral dose of Intelence tablets is 200 mg (two 100mg tablets) twice daily following a meal.

Sandoz has launched fomepizole, a generic version of Jazz Pharmaceuticals’ Antizol. Antizol is an injectable drug for the treatment of ethylene glycol or methanol poisoning. According to Jazz Pharmaceuticals’ full year earnings results, the drug generated sales of approximately $14 million in 2007. The company intends to market generic Antizol in 1.5 gm/1.5 mL single-dose vials.